Paradigm Therapeutics Named Prix Galien Finalist
The firm’s treatment for epidermolysis bullosa, SD-101, earned recognition for its clinical progress.
Updated on Oct. 13, 2026 in Biotech
Live Poll
Should the public place higher priority on supporting new companies developing treatments for rare diseases?
Paradigm Therapeutics has been named a finalist for the 2026 Prix Galien USA Best Start-Up Award, marking its second consecutive year of recognition. The nomination follows the company's development of SD-101, an investigational therapy targeting multiple subtypes of epidermolysis bullosa.
Why it matters
The recognition underscores the progress of SD-101 in treating a rare genetic skin condition, positioning the company to potentially receive a Priority Review Voucher upon regulatory approval. This selection highlights the clinical development trajectory of therapies currently navigating the FDA approval process.
Clinical studies for SD-101 involved 217 pediatric and adult patients across Simplex, Dystrophic, and Junctional EB subtypes. The treatment was applied daily over the entire body for a duration of three months.
The players
Paradigm Therapeutics
A Mount Pleasant-based biotech company focused on developing therapies for rare skin conditions like epidermolysis bullosa.
The Galien Foundation
The organization responsible for managing the Prix Galien awards, which recognize significant advancements in biopharmaceutical research.
The details
SD-101, also known as Zorblesia, is a topical therapeutic designed to address the symptoms of epidermolysis bullosa—a group of rare genetic conditions that cause the skin to be extremely fragile and prone to blistering. The therapy has received Breakthrough Therapy, Rare Pediatric Disease, and Orphan Drug designations from the FDA, alongside Orphan Drug status from the European Commission. A confirmatory study is currently underway focusing specifically on pediatric patients, including those as young as 28 days old.
Timeline
2025: Paradigm Therapeutics received a previous award nomination.
October 14, 2026: Paradigm Therapeutics announced the 2026 award nomination.
October 29, 2026: The Prix Galien USA Awards ceremony will take place.
The Tech Race
This nomination reflects the increasing industry focus on targeting rare genetic skin disorders through specialized regulatory pathways. It positions Paradigm Therapeutics alongside other firms utilizing the FDA Rare Pediatric Disease designation to expedite development toward potential market approval.
For patients suffering from epidermolysis bullosa, the success of SD-101 represents a potential shift in standard-of-care options. Availability remains pending, as the therapy is still undergoing confirmatory studies before final regulatory review.
The takeaway
The nomination validates the company's clinical research progress toward establishing a treatment for epidermolysis bullosa. Readers should track the outcome of the upcoming October 29, 2026 award ceremony and subsequent regulatory filings for SD-101.
What happens next
The Prix Galien USA Awards ceremony is scheduled to occur on October 29, 2026.
Further reading
For broader insights into the current landscape of therapeutic innovation, visit the Biotech section.
More information
View complete clinical therapy details on the Paradigm Therapeutics clinical therapy information portal.
Live Poll
Should the public place higher priority on supporting new companies developing treatments for rare diseases?
